BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 20551270)

  • 1. JAK2 mutations across a spectrum of venous thrombosis cases.
    Shetty S; Kulkarni B; Pai N; Mukundan P; Kasatkar P; Ghosh K
    Am J Clin Pathol; 2010 Jul; 134(1):82-5. PubMed ID: 20551270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of JAK29V617F) mutation in intra-abdominal venous thrombosis.
    Deepak A; Punamiya S; Patel N; Parekh S; Mehta S; Shah N
    Trop Gastroenterol; 2011; 32(4):279-84. PubMed ID: 22696908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic value of the JAK2 V617F mutation for latent chronic myeloproliferative disorders in patients with Budd-Chiari syndrome and/or portal vein thrombosis.
    Karaköse S; Oruç N; Zengin M; Akarca US; Ersöz G
    Turk J Gastroenterol; 2015 Jan; 26(1):42-8. PubMed ID: 25698270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of Janus Kinase 2 mutations in patients with unusual site venous thrombosis.
    Basquiera AL; Tabares AH; Soria N; Salguero M; Ryser R; García JJ
    Medicina (B Aires); 2011; 71(4):313-6. PubMed ID: 21893442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Absence of the JAK2 exon 12 mutations in patients with splanchnic venous thrombosis and without overt myeloproliferative neoplasms.
    Fiorini A; Chiusolo P; Rossi E; Za T; De Ritis DG; Ciminello A; Leone G; De Stefano V
    Am J Hematol; 2009 Feb; 84(2):126-7. PubMed ID: 19105231
    [No Abstract]   [Full Text] [Related]  

  • 6. Prevalence of the JAK2 V617F mutation associated with splanchnic vein thrombosis. A 10-year retrospective study.
    Tondeur S; Boutruche S; Biron-Andréani C; Schved JF
    Thromb Haemost; 2009 Apr; 101(4):787-9. PubMed ID: 19350131
    [No Abstract]   [Full Text] [Related]  

  • 7. Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders.
    De Stefano V; Fiorini A; Rossi E; Za T; Farina G; Chiusolo P; Sica S; Leone G
    J Thromb Haemost; 2007 Apr; 5(4):708-14. PubMed ID: 17263783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis.
    Primignani M; Barosi G; Bergamaschi G; Gianelli U; Fabris F; Reati R; Dell'Era A; Bucciarelli P; Mannucci PM
    Hepatology; 2006 Dec; 44(6):1528-34. PubMed ID: 17133457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is the JAK2 V617F mutation a hallmark for different forms of thrombosis?
    Zerjavic K; Zagradisnik B; Stangler Herodez S; Lokar L; Glaser Krasevac M; Kokalj Vokac N
    Acta Haematol; 2010; 124(1):49-56. PubMed ID: 20616539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The JAK2(V617F) tyrosine kinase mutation identifies clinically latent myeloproliferative disorders in patients presenting with hepatic or portal vein thrombosis.
    Goulding C; Uttenthal B; Foroni L; Duke V; Traore A; Kottaridis P; Hoffbrand AV; Patch D; McNamara C
    Int J Lab Hematol; 2008 Oct; 30(5):415-9. PubMed ID: 19046316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Undiagnosed myeloproliferative disease in cases of intra-abdominal thrombosis: the utility of the JAK2 617F mutation.
    P'ng S; Carnley B; Baker R; Kontorinis N; Cheng W
    Clin Gastroenterol Hepatol; 2008 Apr; 6(4):472-5. PubMed ID: 18328792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meta-analysis: the significance of screening for JAK2V617F mutation in Budd-Chiari syndrome and portal venous system thrombosis.
    Qi X; Yang Z; Bai M; Shi X; Han G; Fan D
    Aliment Pharmacol Ther; 2011 May; 33(10):1087-103. PubMed ID: 21395632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. JAK2(V617F) positive early stage myeloproliferative disease (essential thrombocythemia) as the cause of portal vein thrombosis in two middle-aged women: therapeutic implications in view of the literature.
    Michiels JJ; Commandeur S; Hoogenboom GJ; Wegman JJ; Scholten L; van Rijssel RH; De Raeve H
    Ann Hematol; 2007 Nov; 86(11):793-800. PubMed ID: 17687555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcome of patients with splanchnic venous thrombosis presenting without overt MPN: a role for the JAK2 V617F mutation re-evaluation.
    Colaizzo D; Amitrano L; Guardascione MA; Tiscia GL; D'Andrea G; Longo VA; Grandone E; Margaglione M
    Thromb Res; 2013 Aug; 132(2):e99-e104. PubMed ID: 23916380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome.
    Patel RK; Lea NC; Heneghan MA; Westwood NB; Milojkovic D; Thanigaikumar M; Yallop D; Arya R; Pagliuca A; Gäken J; Wendon J; Heaton ND; Mufti GJ
    Gastroenterology; 2006 Jun; 130(7):2031-8. PubMed ID: 16762626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis.
    Colaizzo D; Amitrano L; Tiscia GL; Scenna G; Grandone E; Guardascione MA; Brancaccio V; Margaglione M
    J Thromb Haemost; 2007 Jan; 5(1):55-61. PubMed ID: 17059429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. JAK2V617F mutation screening as part of the hypercoagulable work-up in the absence of splanchnic venous thrombosis or overt myeloproliferative neoplasm: assessment of value in a series of 664 consecutive patients.
    Pardanani A; Lasho TL; Hussein K; Schwager SM; Finke CM; Pruthi RK; Tefferi A
    Mayo Clin Proc; 2008 Apr; 83(4):457-9. PubMed ID: 18380991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Should We Screen for Janus Kinase 2 V617F Mutation in Cerebral Venous Thrombosis?
    Lamy M; Palazzo P; Agius P; Chomel JC; Ciron J; Berthomet A; Cantagrel P; Prigent J; Ingrand P; Puyade M; Neau JP
    Cerebrovasc Dis; 2017; 44(3-4):97-104. PubMed ID: 28609766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. JAK2 mutation: The best diagnostic tool for myeloproliferative disease in splanchnic vein thrombosis?
    Janssen HL; Leebeek FW
    Hepatology; 2006 Dec; 44(6):1391-3. PubMed ID: 17133464
    [No Abstract]   [Full Text] [Related]  

  • 20. High prevalence of the JAK2 V617F mutation in patients with extrahepatic portal vein thrombosis.
    De Stefano V; Fiorini A; Rossi E; Za T; Chiusolo P; Sica S; Leone G
    Hepatology; 2007 Mar; 45(3):831-2; author reply 832-3. PubMed ID: 17326212
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.